Eli Lilly (LLY)
(Delayed Data from NYSE)
$806.06 USD
-0.08 (-0.01%)
Updated Nov 5, 2024 04:00 PM ET
After-Market: $804.12 -1.94 (-0.24%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth D Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$806.06 USD
-0.08 (-0.01%)
Updated Nov 5, 2024 04:00 PM ET
After-Market: $804.12 -1.94 (-0.24%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth D Momentum C VGM
Zacks News
Lilly (LLY) COVID-19 Antibody Bamlanivimab Gets CHMP Nod
by Zacks Equity Research
CHMP recommends approval of Eli Lilly's (LLY) COVID-19 antibody bamlanivimab, alone and in combination with etesevimab in Europe.
Eli Lilly (LLY) Stock Moves -0.72%: What You Should Know
by Zacks Equity Research
Eli Lilly (LLY) closed the most recent trading day at $200.54, moving -0.72% from the previous trading session.
Biotech Stock Roundup: REGN, VIR's COVID-19 Updates, KMPH's Drug Approval & More
by Zacks Equity Research
The biotech sector was in focus last week with regulatory and pipeline updates from quite a few companies like Regeneron (REGN), Vir (VIR) and KemPharm, Inc. (KMPH).
Biohaven (BHVN) Q4 Earnings Miss, Nurtec Uptake Promising
by Zacks Equity Research
Biohaven's (BHVN) recently approved migraine drug, Nurtec ODT, continues to demonstrate strong launch uptake.
Why Is Lilly (LLY) Down 2.5% Since Last Earnings Report?
by Zacks Equity Research
Lilly (LLY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Eli Lilly (LLY) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Eli Lilly (LLY) closed at $204.89 in the latest trading session, marking a +0.52% move from the prior day.
Radius' (RDUS) Q4 Loss Wider Than Expected, Revenues Beat
by Zacks Equity Research
Radius (RDUS) reports a wider loss but beats sales estimates in the fourth quarter.
Nektar (NKTR) Q4 Earnings and Revenues Top, Pipeline On Track
by Zacks Equity Research
Nektar (NKTR) reports encouraging fourth-quarter 2020 results. The company plans to initiate a new registrational study on its lead pipeline candidate, bempegaldesleukin, in 2021.
United Therapeutics (UTHR) Q4 Earnings Miss, Sales Beat
by Zacks Equity Research
United Therapeutics' (UTHR) fourth-quarter earnings miss estimates while sales beat the same. Higher sales of Orenitram, Remodulin and Tyvaso offset lower sales of Unituxin and Adcirca.
2 Large Cap Stocks to Buy for Income and Growth Amid Tech Volatility
by Benjamin Rains
Investors might want to add a few large cap names outside of the tech world that also provide income through solid dividend yields...
FDA Issues New Guidelines for COVID-19 Vaccines, Tests, Drugs
by Kinjel Shah
The FDA encourages companies to evaluate the impact of COVID-19 virus variants on the efficacy or performance of their COVID-19 vaccines, tests and medicines.
RedHill (RDHL) Doses First Patient in Phase II/III COVID-19 Study
by Zacks Equity Research
RedHill (RDHL) doses first patient in phase II/III study of orally-administered RHB-107 (upamostat), an investigational new drug for patients with symptomatic COVID-19 who do not require hospital care.
Pharma Stock Roundup: Coronavirus Vaccine Updates From PFE, AZN & JNJ
by Kinjel Shah
WHO authorizes emergency use of AstraZeneca's (AZN) COVID-19 vaccine. J&J (JNJ) seeks conditional approval for its COVID-19 vaccine in EU.
Nektar (NKTR) Teams Up With Merck for Head & Neck Cancer Study
by Zacks Equity Research
Nektar's (NKTR) shares up following a deal with Merck for a combination study of bempegaldesleukin with Keytruda for advanced head and neck cancer study.
3 Great Blue Chip Dividend Stocks to Buy Now with Dow at Records
by Benjamin Rains
Investors should always be on the lookout for ways to diversify and bolster their portfolios. One great place to start is with large cap stocks that pay solid dividends...
The Zacks Analyst Blog Highlights: AstraZeneca, Eli Lilly, Sanofi, GlaxoSmithKline and Novartis
by Zacks Equity Research
The Zacks Analyst Blog Highlights: AstraZeneca, Eli Lilly, Sanofi, GlaxoSmithKline and Novartis
Pharma Stock Roundup: AZN's Q4 Earnings, FDA Approval for LLY & SNY's Drugs
by Kinjel Shah
AstraZeneca (AZN) announces Q4 results. FDA approves Lilly's COVID-19 antibody cocktail & Sanofi's (SNY) Libtayo for a new indication.
Lilly (LLY) COVID-19 Antibody Combo Gets FDA's Emergency Nod
by Zacks Equity Research
FDA grants EUA to Eli Lilly's (LLY) COVID-19 antibody cocktail. FDA also authorizes shortened infusion time for bamlanivimab/etesevimab.
ABBV or LLY: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
ABBV vs. LLY: Which Stock Is the Better Value Option?
Pharma ETFs in Focus Post Q4 Earnings
by Sweta Killa
Healthcare Q4 results seem robust given that it is the fourth-best sector from a revenue growth look and the sixth-strongest in terms of earnings growth.
Pharma Stock Roundup: PFE, MRK Q4 Earnings, AZN, JNJ Coronavirus Vaccine Updates
by Kinjel Shah
Several companies announce Q4 results. J&J (JNJ) and AstraZeneca (AZN) provide updates on their respective COVID-19 vaccines.
The Zacks Analyst Blog Highlights: Adobe, Toyota Motor, QUALCOMM, Eli Lilly and PetroChina
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Adobe, Toyota Motor, QUALCOMM, Eli Lilly and PetroChina
Top Analyst Reports for Adobe, Toyota & QUALCOMM
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Adobe (ADBE), Toyota (TM), and QUALCOMM (QCOM).
Tiziana (TLSA) Posts Positive Data on Nasal COVID-19 Antibody
by Zacks Equity Research
Tiziana (TLSA) reports positive data from a study investigating its anti-CD3 human monoclonal antibody, foralumab (nasally administered) for treating COVID-19 patients in Brazil. Shares up.
Novo Nordisk's (NVO) Q4 Earnings and Sales Beat Estimates
by Zacks Equity Research
Novo Nordisk (NVO) beats both earnings and sales estimates for the fourth quarter of 2020.